Progress of pruritus research in atopic dermatitis

Biomolecules and Therapeutics

Volumn 18, Issue 3, 2010, Pages 246-256

  Lee, Chang Hoon ^a  

^a Dongguk University   (South Korea)

Author keywords

Antipruritic therapy; Atopic dermatitis; New target; Pruritogen; Pruritus

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; ASCOMYCIN; BUTORPHANOL; CAPSAICIN; CETIRIZINE; CHLOROQUINE; CYCLOSPORIN A; DOXEPIN; GABAPENTIN; GASTRIN RELEASING PEPTIDE; HISTAMINE; KETANSERIN TARTRATE; LEUKOTRIENE; MENTHOL; MIRTAZAPINE; MONTELUKAST; MORPHINE; MYCOPHENOLIC ACID; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NALTREXONE; PAROXETINE; PLACEBO; PROSTAGLANDIN E; SEROTONIN; SPHINGOSYLPHOSPHORYLCHOLINE; TACROLIMUS; THALIDOMIDE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE A2;

APPLICATION SITE IRRITATION; ARTICLE; ATOPIC DERMATITIS; CONTACT ALLERGY; CONTINUOUS INFUSION; DISEASE CONTROL; DROWSINESS; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ECZEMA; HUMAN; KERATINOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PRURITUS; SKIN INFLAMMATION;

EID: 77957329125     PISSN: 19769148     EISSN: None     Source Type: Journal    
DOI: 10.4062/biomolther.2010.18.3.246     Document Type: Article

References (84)

1. Abeck, D., Andersson, T., Grosshans, E., Jablonska, S., Kragballe, K., Vahlquist, A., Schmidt, T., Dupuy, P. and Ring, J. (1997). Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis. Acta. Derm. Venereol. 77, 449-451.
2. Alenmyr, L., Hogestatt, E. D., Zygmunt, P. M. and Greiff, L. (2009). TRPV1-mediated itch in seasonal allergic rhinitis. Allergy 64, 807-810.
3. Andoh, T. (2008). Mechanisms of cutaneous itch: new itch mediators and enhancement factors produced by keratinocytes. Nippon Yakurigaku Zasshi 131, 361-366.
4. Andoh, T. and Kuraishi, Y. (1998). Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur. J. Pharmacol. 353, 93-96.
5. Andoh, T. and Kuraishi, Y. (2005). Expression of BLT1 leukotriene B4 receptor on the dorsal root ganglion neurons in mice. Brain Res. Mol. Brain Res. 137, 263-266.
6. Andoh, T., Nishikawa, Y., Yamaguchi-Miyamoto, T., Nojima, H., Narumiya, S. and Kuraishi, Y. (2007). Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice. J. Invest Dermatol. 127, 2042-2047.
7. Andoh, T., Saito, A. and Kuraishi, Y. (2009). Leukotriene B(4) mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin. J. Invest. Dermatol. 129, 2854-2860.
8. Badertscher, K., Bronnimann, M., Karlen, S., Braathen, L. R. and Yawalkar, N. (2005). Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch. Dermatol. Res. 296, 503-506.
9. Ballmer-Weber, B. K. and Dummer, R. (2007). Pruritus in frequent skin diseases and therapeutic options. Praxis (Bern 1994) 96, 107-111.
10. Biro, T., Toth, B. I., Marincsak, R., Dobrosi, N., Geczy, T. and Paus, R. (2007). TRP channels as novel players in the pathogenesis and therapy of itch. Biochim. Biophys. Acta. 1772, 1004-1021.
11. Capella, G. L., Grigerio, E. and Altomare, G. (2001). A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur. J. Dermatol. 11, 209-213.
12. Carucci, J. A., Washenik, K., Weinstein, A., Shupack, J. and Cohen, D. E. (1998). The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch. Dermatol. 134, 785-786.
13. Choi, H., Kim, S., Kim, H. J., Kim, K. M., Lee, C. H., Shin, J. H. and Noh, M. (2010). Sphingosylphosphorylcholine downregulates filaggrin gene transcription through NOX5-based NADPH oxidase and cyclooxygenase-2 in human keratinocytes. Biochem. Pharmacol. 80, 95-103.
14. Cowden, J. M., Zhang, M., Dunford, P. J. and Thurmond, R. L. (2010). The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J. Invest. Dermatol. 130, 1023-1033.
15. Czarnetzki, B. M. and Csato, M. (1989). Comparative studies of human eosinophil migration towards platelet-activating factor and leukotriene B4. Int. Arch. Allergy Appl. Immunol. 88, 191-193.
16. Daly, B. M. and Shuster, S. (2000). Antipruritic action of thalidomide. Acta. Derm. Venereol. 80, 24-25.
17. Davis, M. P., Frandsen, J. L., Walsh, D., Andresen, S. and Taylor, S. (2003). Mirtazapine for pruritus. J. Pain Symptom. Manage 25, 288-291.
18. Dawn, A. G. and Yosipovitch, G. (2006). Butorphanol for treatment of intractable pruritus. J. Am. Acad. Dermatol. 54, 527-531.
19. de Oliveira, M. S., Cechim, G., Braganhol, E., Santos, D. G., Meurer, L., de Castro, C. G. Jr., Brunetto, A. L., Schwartsmann, G., Battastini, A. M., Lenz, G. and Roesler, R. (2009). Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J. Neurooncol. 93, 191-201.
20. Dhaka, A., Viswanath, V. and Patapoutian, A. (2006). Trp ion channels and temperature sensation. Annu. Rev. Neurosci. 29, 135-161.
21. Dunford, P. J., Williams, K. N., Desai, P. J., Karlsson, L., McQueen, D. and Thurmond, R. L. (2007). Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J. Allergy Clin. Immunol. 119, 176-183.
22. Ellis, C. N., Drake, L. A., Prendergast, M. M., Abramovits, W., Boguniewicz, M., Daniel, C. R., Lebwohl, M., Stevens, S. R., Whitaker-Worth, D. L., Cheng, J. W. and Tong, K. B. (2002). Cost of atopic dermatitis and eczema in the United States. J. Am. Acad. Dermatol. 46, 361-370.
23. Figueiredo, A., Ribeiro, C. A., Goncalo, M., Almeida, L., Poiares-Baptista, A. and Teixeira, F. (1990). Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam. Clin. Pharmacol. 4, 147-158.
24. Fitzsimons, E. J., Dagg, J. H. and McAllister, E. J. (1981). Pruritus of polycythaemia vera: a place for pizotifen? Br. Med. J. (Clin Res Ed) 283, 277.
25. Fjellner, B. and Hagermark, O. (1979). Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. Acta. Derm. Venereol. 59, 505-512.
26. Fjellner, B. and Hagermark, O. (1985). Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. Acta. Derm. Venereol. 65, 409-412.
27. Folster-Holst, R. and Christophers, E. (2001). Antipruritic therapy in atopic eczema. Hautarzt. 52, 853-861.
28. Gazerani, P., Pedersen, N. S., Drewes, A. M. and Arendt-Nielsen, L. (2009). Botulinum toxin type A reduces histamineinduced itch and vasomotor responses in human skin. Br. J. Dermatol. 161, 737-745.
29. Greaves, M. W. (2007). Recent advances in pathophysiology and current management of itch. Ann. Acad. Med. Singapore 36, 788-792.
30. Gunal, A. I., Ozalp, G., Yoldas, T. K., Gunal, S. Y., Kirciman, E. and Celiker, H. (2004). Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol. Dial. Transplant 19, 3137-3139.
31. Hanifin, J. M., Chan, S. C., Cheng, J. B., Tofte, S. J., Henderson, W. R. Jr., Kirby, D. S. and Weiner, E. S. (1996). Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol. 107, 51-56.
32. Hashimoto, T., Ohata, H. and Momose, K. (2004). Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology 72, 51-56.
33. Hashimoto, T., Ohata, H., Momose, K. and Honda, K. (2005). Lysophosphatidic acid induces histamine release from mast cells and skin fragments. Pharmacology 75, 13-20.
34. Heyer, G. R. and Hornstein, O. P. (1999). Recent studies of cutaneous nociception in atopic and non-atopic subjects. J. Dermatol. 26, 77-86.
35. Imokawa, G., Takagi, Y., Higuchi, K., Kondo, H. and Yada, Y. (1999). Sphingosylphosphorylcholine is a potent inducer of intercellular adhesion molecule-1 expression in human keratinocytes. J. Invest. Dermatol. 112, 91-96.
36. Jiang, J., Kuhara, T., Ueki, R., Zheng, Y., Suto, H., Ikeda, S. and Ogawa, H. (2007). Inhibitory effects of paroxetine on the development of atopic dermatitis-like lesions in NC/Nga mice. J. Dermatol. Sci. 47, 244-247.
37. Jones, E. A. and Bergasa, N. V. (2000). Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. Can. J. Gastroenterol. 14, 33-40.
38. Kim, B. M., Lee, S. H., Shim, W. S. and Oh, U. (2004). Histamineinduced Ca(2+) influx via the PLA(2)/lipoxygenase/TRPV1 pathway in rat sensory neurons. Neurosci. Lett. 361, 159-162.
39. Kim, D. K., Kim, H. J., Kim, H., Koh, J. Y., Kim, K. M., Noh, M. S., Kim, J. J. and Lee, C. H. (2008a). Involvement of serotonin receptors 5-HT1 and 5-HT2 in 12(S)-HPETEinduced scratching in mice. Eur. J. Pharmacol. 579, 390-394.
40. Kim, D. K., Kim, H. J., Sung, K. S., Kim, H., Cho, S. A., Kim, K. M., Lee, C. H. and Kim, J. J. (2007). 12(S)-HPETE induces itch-associated scratchings in mice. Eur. J. Pharmacol. 554, 30-33.
41. Kim, H. J., Kim, D. K., Kim, H., Koh, J. Y., Kim, K. M., Noh, M. S., Lee, S., Kim, S., Park, S. H., Kim, J. J., Kim, S. Y. and Lee, C. H. (2008b). Involvement of the BLT2 receptor in the itch-associated scratching induced by 12-(S)-lipoxygenase products in ICR mice. Br. J. Pharmacol. 154, 1073-1078.
42. Kim, H. J., Kim, H., Han, E. S., Park, S. M., Koh, J. Y., Kim, K. M., Noh, M. S., Kim, J. J. and Lee, C. H. (2008c). Characterizations of sphingosylphosphorylcholine-induced scratching responses in ICR mice using naltrexon, capsaicin, ketotifen and Y-27632. Eur. J. Pharmacol. 583, 92-96.
43. Kim, H. J., Kim, K. M., Koh, J. Y., Noh, M. S., Park, M. K., Lee, H. J., Kim, S. Y. and Lee, C. H. (2010). Sphingosylphosphorylcholine induces degranulation of mast cells in the skin and plasma exudation in the ears of mice. J. Dermatol. Sci. 57, 57-59.
44. Leung, D. Y. and Soter, N. A. (2001). Cellular and immunologic mechanisms in atopic dermatitis. J. Am. Acad. Dermatol. 44, S1-S12.
45. Lewis-Jones, S. (2005). Measuring the burden of atopic eczema in young children and the family unit. J. Invest. Dermatol. 125, viii.
46. Li, W. H., Lee, Y. M., Kim, J. Y., Kang, S., Kim, S., Kim, K. H., Park, C. H. and Chung, J. H. (2007). Transient receptor potential vanilloid-1 mediates heat-shock-induced matrix metalloproteinase-1 expression in human epidermal keratinocytes. J. Invest. Dermatol. 127, 2328-2335.
47. Liu, Q., Tang, Z., Surdenikova, L., Kim, S., Patel, K. N., Kim, A., Ru, F., Guan, Y., Weng, H. J., Geng, Y., Undem, B. J., Kollarik, M., Chen, Z. F., Anderson, D. J. and Dong, X. (2009). Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 139, 1353-1365.
48. Lovell, C. R., Burton, P. A., Duncan, E. H. and Burton, J. L. (1976). Prostaglandins and pruritus. Br. J. Dermatol. 94, 273-275.
49. Lynde, C. B., Kraft, J. N. and Lynde, C. W. (2008). Novel agents for intractable itch. Skin Therapy Lett. 13, 6-9.
50. Malekzad, F., Arbabi, M., Mohtasham, N., Toosi, P., Jaberian, M., Mohajer, M., Mohammadi, M. R., Roodsari, M. R. and Nasiri, S. (2009). Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 23, 948-950.
51. Metze, D., Reimann, S., Beissert, S. and Luger, T. (1999). Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J. Am. Acad. Dermatol. 41, 533-539.
52. Miyoshi, M., Sakurai, T. and Kodama, S. (1999). Clinical evaluation of urinary leukotriene E4 levels in children with atopic dermatitis. Arerugi. 48, 1148-1152.
53. Neisius, U., Olsson, R., Rukwied, R., Lischetzki, G. and Schmelz, M. (2002). Prostaglandin E2 induces vasodilation and pruritus, but no protein extravasation in atopic dermatitis and controls. J. Am. Acad. Dermatol. 47, 28-32.
54. Okuno, T., Iizuka, Y., Okazaki, H., Yokomizo, T., Taguchi, R. and Shimizu, T. (2008). 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J. Exp. Med. 205, 759-766.
55. Peier, A. M., Reeve, A. J., Andersson, D. A., Moqrich, A., Earley, T. J., Hergarden, A. C., Story, G. M., Colley, S., Hogenesch, J. B., McIntyre, P., Bevan, S. and Patapoutian, A. (2002). A heat-sensitive TRP channel expressed in keratinocytes. Science 296, 2046-2049.
56. Price, M. M., Oskeritzian, C. A., Milstien, S. and Spiegel, S. (2008). Sphingosine-1-phosphate synthesis and functions in mast cells. Future Lipidol. 3, 665-674.
57. Rukwied, R., Lischetzki, G., McGlone, F., Heyer, G. and Schmelz, M. (2000). Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br. J. Dermatol. 142, 1114-1120.
58. Ryu, S. D., Lee, H. S., Suk, H. Y., Park, C. S. and Choi, O. H. (2009). Cross-linking of FcepsilonRI causes Ca2+ mobilization via a sphingosine kinase pathway in a clathrindependent manner. Cell Calcium. 45, 99-108.
59. Schmelz, M. (2001). A neural pathway for itch. Nat. Neurosci. 4, 9-10.
60. Schworer, H. and Ramadori, G. (1995). Cholestatic pruritus-- pathophysiology and therapy with special reference to treatment with 5-hydroxytryptamine subtype 3 receptor antagonists. Z. Gastroenterol. 33, 265-274.
61. Shelley, W. B., Shelley, E. D. and Talanin, N. Y. (1996). Self potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J. Am. Acad. Dermatol. 34, 143-144.
62. Shimada, S. G., Shimada, K. A. and Collins, J. G. (2006). Scratching behavior in mice induced by the proteinaseactivated receptor-2 agonist, SLIGRL-NH2. Eur. J. Pharmacol. 530, 281-283.
63. Sotomayor, S., Munoz-Moreno, L., Carmena, M. J., Schally, A. V., Sanchez-Chapado, M., Prieto, J. C. and Bajo, A. M. (2010). Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095). Int. J. Cancer. in press.
64. Stander, S. and Steinhoff, M. (2002). Pathophysiology of pruritus in atopic dermatitis: an overview. Exp. Dermatol. 11, 12-24.
65. Steinhoff, M., Neisius, U., Ikoma, A., Fartasch, M., Heyer, G., Skov, P. S., Luger, T. A. and Schmelz, M. (2003). Proteinaseactivated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J. Neurosci. 23, 6176-6180.
66. Steinhoff, M., Vergnolle, N., Young, S. H., Tognetto, M., Amadesi, S., Ennes, H. S., Trevisani, M., Hollenberg, M. D., Wallace, J. L., Caughey, G. H., Mitchell, S. E., Williams, L. M., Geppetti, P., Mayer, E. A. and Bunnett, N. W. (2000). Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat. Med. 6, 151-158.
67. Summey, B. T., Jr. and Yosipovitch, G. (2005). Pharmacologic advances in the systemic treatment of itch. Dermatol. Ther. 18, 328-332.
68. Sun, Y. G. and Chen, Z. F. (2007). A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 448, 700-703.
69. Sun, Y. G., Zhao, Z. Q., Meng, X. L., Yin, J., Liu, X. Y. and Chen, Z. F. (2009). Cellular basis of itch sensation. Science 325, 1531-1534.
70. Swain, M. G. (2008). Gastrin-releasing peptide and pruritus: more than just scratching the surface. J. Hepatol. 48, 681-683.
71. Taskapan, M. O. (2001). Zileuton and atopic dermatitis. Ann. Allergy Asthma. Immunol. 87, 162-163.
72. Tigyi, G. and Parrill, A. L. (2003). Molecular mechanisms of lysophosphatidic acid action. Prog. Lipid Res. 42, 498-526.
73. Tominaga, M., Ozawa, S., Ogawa, H. and Takamori, K. (2007). A hypothetical mechanism of intraepidermal neurite formation in NC/Nga mice with atopic dermatitis. J. Dermatol. Sci. 46, 199-210.
74. Tsujii, K., Andoh, T., Lee, J. B. and Kuraishi, Y. (2008). Activation of proteinase-activated receptors induces itch-associated response through histamine-dependent and -independent pathways in mice. J. Pharmacol. Sci. 108, 385-388.
75. Weidner, C., Klede, M., Rukwied, R., Lischetzki, G., Neisius, U., Skov, P. S., Petersen, L. J. and Schmelz, M. (2000). Acute effects of substance P and calcitonin gene-related peptide in human skin-a microdialysis study. J. Invest. Dermatol. 115, 1015-1020.
76. Weisshaar, E., Ziethen, B. and Gollnick, H. (1997). Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally- induced itch? Inflamm. Res. 46, 412-416.
77. Woodmansee, D. P. and Simon, R. A. (1999). A pilot study examining the role of zileuton in atopic dermatitis. Ann. Allergy Asthma. Immunol. 83, 548-552.
78. Yamaura, K., Oda, M., Suwa, E., Suzuki, M., Sato, H. and Ueno, K. (2009). Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist. J. Toxicol. Sci. 34, 427-431.
79. Yokoyama, Y., Yokoyama, T., Nagao, Y., Nakagawa, T. and Magaribuchi, T. (2009). Treatment of epidural morphine induced pruritus with butorphanol. Masui. 58, 178-182.
80. Yosipovitch, G. and Papoiu, A. D. (2008). What causes itch in atopic dermatitis? Curr. Allergy. Asthma. Rep. 8, 306-311.
81. Yosipovitch, G., Szolar, C., Hui, X. Y. and Maibach, H. (1996). High-potency topical corticosteroid rapidly decreases histamine- induced itch but not thermal sensation and pain in human beings. J. Am. Acad. Dermatol. 35, 118-120.
82. Yu, B., Shao, Y., Zhang, J., Dong, X. L., Liu, W. L., Yang, H., Liu, L., Li, M. H., Yue, C. F., Fang, Z. Y., Zhang, C., Hu, X. P., Chen, B. C., Wu, Q., Chen, Y. W., Zhang, W. and Wan, J. (2010). Polymorphisms in human histamine receptor H4 gene are associated with atopic dermatitis. Br. J. Dermatol. 162, 1038-1043.
83. Zhang, X., Bao, L. and Ma, G. Q. (2010). Sorting of neuropeptides and neuropeptide receptors into secretory pathways. Prog. Neurobiol. 90, 276-283.
84. Zylicz, Z., Krajnik, M., Sorge, A. A. and Costantini, M. (2003). Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J. Pain. Symptom. Manage 26, 1105-1112.